Low-Dose Sulfonylurea Plus DPP4 Inhibitor Lower Blood Glucose and Enhance Beta-Cell Function Without Hypoglycemia.

Ruth Lorna Mary CordinerKhaled BedairAndrea Mari Ewan R Pearson

Published in: The Journal of clinical endocrinology and metabolism (2024)

Low-dose sulfonylurea plus DPP4i has a potent glucose-lowering effect through augmentation of beta-cell function. A double-blind randomized controlled trial would formalize efficacy and safety of this combination, which may avoid negative aspects of SU.

Keyphrases

blood glucose
low dose
glycemic control
randomized controlled trial
high dose
type diabetes
blood pressure
study protocol
soft tissue
weight loss
clinical trial
skeletal muscle